Drugmaker Lykos Therapeutics had asked the FDA to approve its MDMA capsules as part of a therapy regimen they argued could be a breakthrough for treating challenging cases of PTSD. Lykos said the ...

The U.S. Food and Drug Administration (FDA) has decided not to approve a psychedelic treatment -- along with therapy -- to treat post-traumatic stress disorder (PTSD), according to Lykos ...

The U.S. Food and Drug Administration (FDA) announced Friday its rejection of MDMA as a treatment for PTSD. The decision was based on "significant limitations" that "prevent the agency from ...

In June, the FDA's Psychopharmacologic Drugs Advisory Committeevoted 9-2 against MDMA as an effective treatment for PTSD patients, and 10-1 that the drug's benefits do not outweigh the risks.

FDA Rejects Psychedelic MDMA as Treatment for PTSD, Calling for Additional Study WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy ...

WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy for PTSD, a major setback for groups seeking a breakthrough decision in favor of ...

There are only two FDA-approved treatments for PTSD. MDMA would be the first to come on the market in decades. Though classified as a Schedule I drug, the FDA granted MDMA "breakthrough therapy ...

Drugmaker Lykos Therapeutics had asked the FDA to approve its MDMA capsules as part of a therapy regimen for treating PTSD. It says another study will take "several years." ...

MDMA came close to becoming medicine on Friday, but it missed the mark. The Food and Drug Administration declined to approve what would have been the first psychedelic drug used for the treatment ...

Two small studies submitted to the FDA suggested combining MDMA with talk therapy led to significant easing of PTSD symptoms. Antidepressants are now the only FDA-approved drugs for PTSD ...

WASHINGTON (AP) — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy for PTSD, a major setback for groups seeking a breakthrough decision in favor of ...